Enzamide 80mg Capsule
Prescription Required
Marketed By
Intas
Pack of
14 Capsule in Strip
Salt Composition
Enzalutamide
Storage
Keep in cold place
₹4400₹11500
61.74% Off
Inclusive of all taxes
1
Enzamide 80mg Capsule
Delivering To: —
Description
Enzamide 80mg Capsule is a target therapy based chemotherapeutic medication.It is used to treat Metastatic and Non-Metastatic castration-resistant Prostate Cancer. Enzamide 80mg Capsule contains Enzalutamide salt that works by inhibiting the androgen receptors.As a result, this medication inhibits male hormone driven cancer progression. This medication can only be purchased after a doctor's prescription.
Dosage And Administration
The typical prescribed dosage of Enzamide 80mg Capsule is 160mg daily. It means patient need to consume 2 capsules daily. This medicine is taken orally with the help of water. Avoid breaking, chewing, biting of capsules to maintain its integrity and efficacy. To know about exact dosage and treatment time, visit your doctor for consultation.
Mechanism Of Action
Enzamide 80mg Capsule contains Enzalutamide salt that works by inhibiting the androgen receptors. Androgen receptors are responsible for testosterone hormone production. Blocking of androgen receptor reduces the testosterone hormone that helps in cancer cell growth and proliferation.As a result, this medication inhibits male hormone driven cancer progression. This medication can only be purchased after a doctor's prescription.
Faqs
Enzamide 80mg Capsule is used to treat Metastatic and Non-Metastatic castration-resistant Prostate Cancer.
Yes, Enzamide 80mg Capsule is a hormone therapy based medicine that targets the androgen (male hormones).
Enzamide 80mg Capsule contains Enzalutamide salt that works by inhibiting the androgen receptors.Therefore, prevents androgen production. As a result, cancer cells die due to lack of nutrition provided by hormone.
Enzamide 80mg Capsule contains Enzalutamide salt.
Yes, Enzamide 80mg Capsule is especially for men and not to be consumed by women.
References
• Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., ... & Tombal, B. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine, 371(5), 424-433.
• Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., ... & Sweeney, C. J. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), 121-131.
• Claessens, F., Helsen, C., Prekovic, S., Van den Broeck, T., Spans, L., Van Poppel, H., & Joniau, S. (2014). Emerging mechanisms of enzalutamide resistance in prostate cancer. Nature reviews urology, 11(12), 712-716.
• Moreira, R. B., Debiasi, M., Maluf, F. C., Bellmunt, J., Fay, A. P., Choueiri, T. K., & Schutz, F. A. B. (2016). Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials.
Related Products
MARKETER DETAILS
Intas
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.